2025 Fall Intern - Machine learning for Generative AI

The Department of Translational Medicine leads biomarker discovery and development efforts for programs in Early Stage Research through Phase III clinical trials. We use relevant pharmacodynamic biomarkers to evaluate target-engagement and mechanism of action of candidate therapies as well as prognostic biomarkers to guide patient selection. Our department is responsible for developing biomarker strategies, designing and implementing biomarker assays, and interpreting biomarker results. Biomarker team leaders within the department provide scientific leadership on biomarkers for clinical trials ranging from early proof-of-concept through global Phase III. We are currently seeking a highly-motivated intern to provide computational support on clinical development projects in Lupus. Specifically, the candidate would support the data analysis of pharmacodynamic and clinical biomarker data from various clinical studies to understand the investigational drug's impact on relevant immunological and pathological processes. This internship position is located in South San Francisco, California, on site. We seek a highly motivated intern to join the Computational Sciences organization in Genentech Research and Early Development (gRED). Our group is dedicated to leveraging AI to accelerate drug discovery and target discovery efforts. Our work spans across autonomous agent design and evaluation, large-scale foundation models, with a strong emphasis on scientific discovery, drug development, and complex decision-making pipelines. Responsibilities: Research, design, and implement novel cutting-edge evaluations for agentic systems with applications to drug discovery. Drive research on (large-scale) generative AI methods solving computational biology challenges. Collaborate with cross-functional teams to evaluate LLM based agents and deploy it into impactful applications for drug discovery and target discovery. Opportunity to contribute to publications, presenting results at internal and external scientific conferences.

Genentech, a member of the Roche group and founder of the biotechnology industry, is dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. To solve the world's most complex health challenges, we ask bigger questions that challenge our industry and the boundaries of science to transform society. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis. We celebrate our unique history as the pioneers of scientific breakthroughs that have an incredible track record of improving lives. And yet, our ambitions are bigger and bolder. We are growing a team committed to the bold quest to solve the world's most complex health challenges.